key: cord-0816114-pxll0a7n authors: Kiedrowski, Miroslaw; Kapala, Przemyslaw; Kiedrowska, Marlena; Skoczyńska, Anna; Czerw, Aleksandra; Deptała, Andrzej title: Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19 date: 2020-11-26 journal: Med Hypotheses DOI: 10.1016/j.mehy.2020.110434 sha: 3853d221d82388c910ce6fb3471e37f45a30e210 doc_id: 816114 cord_uid: pxll0a7n Cancer cachexia is a progressive loss of muscle mass (with or without a decrease of adipose tissue). Gradual deterioration of the patient's fitness is resistant to nutritional intervention. The biochemical foundation of observed catabolism, detrimental protein, and energy balance is composite. However, the generalized inflammatory response plays a vital role. It is a kind of cytokine storm, which involves increased activity of TNF-α, IL-1, IL-6, and INF-γ. Pharmacological treatment of cachexia consists mainly of progestagens and glucocorticosteroids. Still, the assessment of new options limiting the harmful impact of cachexia could be beneficial. Chloroquine (CQ) and hydroxychloroquine (HCQ) are old antimalarial agents endowed with immunomodulatory properties. Being potent autophagy inhibitors, they could lead to some kind of intracellular starvation in both immunocompetent effector cells and cancer cells, thus limiting the harmful impact of CC. CQ/HCQ are also efficient in particular connective tissue disorders. They have gained special attention since the World Health Organization announced the coronavirus disease 2019 (COVID-19) pandemic. According to initial reports, people with a severe inflammatory reaction achieved significant benefits. Possibly they could not be attributed to the antiviral activity alone. It is worth noting that the cytokine storm in COVID-19, connective tissue disorders, and cancer cachexia share some similarities. Therefore, we hypothesize that low doses of CQ/HCQ may prove efficient in cancer cachexia. Cancer cachexia (CC) is a result of insufficient food intake, reduced anabolism, and increased catabolism. It reduces the vital forces of the affected person and significantly affects the quality of life. The cytokine storm (TNF-α, IL-1, IL-6, INF-γ), energy-inefficient processes (especially the Cori cycle), myostatin, and zinc-α2-glycoprotein overactivity, insulin resistance, and the consumption of energy substrates by cancer tissue constitute the biochemical basis of the decay processes [1] . The pro-inflammatory cytokine profile also occurs in connective tissue disorders [2, 3] . The emergence of the SARS-CoV-2 pandemic reemphasized the importance of cytokine storms in the etiology of debilitating and frequently lethal conditions. Old antimalarial drugs -chloroquine (CQ) and hydroxychloroquine (HCQ)proved efficient in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) [4] . According to some preliminary studies, they also seemed beneficial in COVID-19 -a syndrome developing in some patients with the SARS-CoV-2 infection [5] [6] [7] [8] . Although initial enthusiasm for their use had diminished significantly, clinical trials are still underway in many countries. Despite the utterly separate etiologies, the cytokines involved in the inflammatory response in cachexia, connective tissue diseases, and COVID-19 are similar [9] . Although the etiology of CC is multifactorial and unclear, the cytokine storm is essential. This term was first employed to describe an impressively powerful activation of the immune system leading to graft versus host disease [10] . Over the years, the term was increasingly used in the medical literature to describe pronounced and frequently life-threatening immune system responses in many conditions. Many classes of compounds are involved in cytokine storms, including: -interferons -a family of cytokines binding with specific receptors, which results in increased expression of antiviral and immunomodulatory proteins, -tumor necrosis factor α (TNF-α) -a pyrogen cytokine released in the acute phase of infections, and associated with many inflammatory and autoimmune conditions, -interleukins -involved in immune cell differentiation, activation, traffic, and production of secondary cytokines [11] . The significant effectiveness of anti-inflammatory agentsglucocorticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and omega-3 fatty acidsindicates that retuning the immune system and cytokine profile may reduce the detrimental impact of cachexia. The cytokine storm in CC, connective tissue disorders and COVID-19 share some similarities. Both chloroquine (CQ) and hydroxychloroquine (HCQ) seem beneficial in the latter two. Moreover, their long-term safety profile is well-known; connective-tissue disorders are chronic and usually incurable, requiring prolonged use of the drugs. Modulating a warped inflammatory reaction is crucial in the CC. Still, other CQ/HCQ properties could be involved. Reducing the lysosomes' acidity and subsequently influencing autophagy may lead to multiple biological consequences on intracellular and higher levels. The question is whether CQ/HCQ could be utilized in CC, too, especially in low doses, and combined with drugs of proven efficacy. Thus, we hypothesize that low doses of both CQ and HCQ may prove efficient in cancer cachexia, especially when combined with well-known agents: progestagens, corticosteroids, and nutritional intervention. According to the most accepted framework, there are three criteria to recognize cancer cachexia: weight loss >5% over the past six months, a body mass index <20 and weight loss >2%, or an appendicular skeletal muscle index consistent with sarcopenia and weight loss >2%. The same consensus distinguishes three stages of CC, namely pre-cachexia, cachexia, and refractory cachexia [12] . So far, few interventions have confirmed their effectiveness in the treatment of CC. These include progestagens, glucocorticosteroids, and some nonsteroidal anti-inflammatory drugs (NSAIDs) [13] [14] [15] [16] . The use of other agents is either not recommended or based on low-quality evidence. Glucocorticosteroids are endowed with pleiotropic properties. They inhibit the synthesis and release of many pro-inflammatory cytokines. They also enhance the neuropeptide Y level and reveal a rapid appetite improvement. Their prolonged use, however, is problematic. It is associated with many side effects (e.g., the risk of gastrointestinal bleeding, post-steroid myopathy, hyperglycemia) [17] . NSAIDs also diminish inflammation, lead to BMI and lean body mass improvement, improve quality of life, and reduce fatigue [16] . Their potential gastrointestinal toxicity limits the broader use of NSAIDs. It seems that omega-3 fatty acids reduce IL-1 and TNF-α concentration. They inhibit glucocorticosteroid-dependent lipolysis, although, according to a systematic review by Dewey et al., they did not prove efficient [18] . It is easy to discover that many drugs used in CC are, in fact, anti-inflammatory agents. Chloroquine was discovered over eight decades ago. Despite its antimalarial activity, it achieved a prominent place as an anti-inflammatory agent in connective tissue diseases. A somewhat later synthesized derivative -hydroxychloroquine -soon became favored due to its superior safety profile [19] . The detailed mechanism of action of those agents is unclear. They inhibit A2 phospholipase, lead to a decrease in the excitation of CD4 lymphocytes, inhibit the release of cytokines, and limit antibody production. CQ/HCQ impact on the cytokine storm is presumably a manifestation of other actions at the subcellular and molecular levels. Thus, several other properties may be of crucial importance: 1. CQ and HCQ are weakly basic drugs, affecting the lysosomes. Those small vesicles surrounded by a single lipid-protein membrane are endowed with H + -ATPase pumps keeping their internal pH around 5. They contain acid hydrolases, which can break down proteins, nucleic acids, carbohydrates, and fats. Lysosomes decompose substances absorbed by endocytosis. They also remove outdated and damaged cellular components, recovering organic substances by autophagy. Autophagy is performed by the formation of temporary sequestering structures (phagophores). They encapsulate components intended for turnover and turn into double-membrane autophagosomes fusing with lysosomes [20] . Autophagy is crucial in degrading large structures such as organelles and protein aggregates [21, 22] . Alkalizing the lysosomes affects cellular digestion. Recently it was demonstrated that chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion [23] . Thus CQ/HCQ are autophagy inhibitors. We speculate that a relative shortage of substrates due to CQ/HCQ administration could limit the catastrophic overactivity of many immunocompetent cells involved in cancer cachexia. 2. Cancer cells utilize autophagy as an additional energy source, especially in an unfavorable metastatic environment. Some clinical trials revealed the promising role of CQ as a novel oncological drug [24] . Both CQ/HCQ can increase sensitivity to radiation and certain chemotherapeutics. To date, they remain the only autophagy inhibitors approved by the Food and Drug Administration (FDA) [25] [26] [27] [28] . Thus, we suppose that autophagy inhibition by 19 is associated with high concentrations of pro-inflammatory cytokines, especially IL-6 [31, 32] . This finding suggests that excessive activation of the immune system in COVID-19 may be catastrophic. Thus, immunomodulatory properties contribute to CQ/HCQ beneficial effect [33, 34] . To date, there is no empirical data concerning CQ/HCQ utilization in CC. The most reliable way to test our hypothesis would be to perform a double-blinded randomized clinical trial (RCT). Adult participants with cachexia/refractory cachexia recruited, first of all, from stationary hospices and able to swallow tablets, would be randomized to two arms. The first arm would receive the standard treatment (e.g., progestagens or corticosteroids plus oral nutritional support) and the tested drug (preferably HCQ). In the second arm, patients would take the same therapeutic regimen plus placebo. Certain doubts arise, however. CQ or HCQ are highly active substances exhibiting adverse effects. The most common are nausea, vomiting, and diarrhea [35, 36] . Some of them could lower the quality of ending life, which could be especially undesirable in this particularly sensitive group. Most of them are dosedependent and usually appear with loading doses of 800 mg of HCQ daily [37] . Other common adverse effects -e.g., retinopathy -are irrelevant in this group of participants due to short life expectancy [38] . Thus, low doses of drugs should be tested first (e.g., 250 mg CQ /200 mg HCQ daily). The proposed end-points could be weight change, specific markers concentrations (e.g., C-reactive protein, pro-inflammatory cytokines), and survival time. Also, standardized self-assessment questionnaires such as EORTC QLQ-30 would help assess the quality of life and multi-dimensional functioning of participants [39] . Before conducting an RCT, we propose a comparative observational study. Comparing the CC in patients already treated with CQ/HCQ due to previously diagnosed autoimmune conditions with the majority without such burdens could be quite informative. However, acquiring a group of the right size would be problematic. Thus, a multi-center observational study could help to achieve sufficient power. Still, there is a risk that the assessment of cachexia symptoms could be biased by the overlapping of cancer and autoimmune disorders' influence. Existing benefits might then be unnoticed. The incidence of CC depends on the tumor type and clinical staging. In pancreatic or gastric cancer patients, its frequency exceeds 80%, while in the lung, colon, or prostate, it is about 50% [40] . Cachexia contributes to at least 20% of cancer-associated deaths. It lowers the quality of life and limits therapeutic options in many patients [41] . Medical therapychemotherapy (especially platinum-based) and radiotherapy -may also contribute to CC development [42] . Moreover, CC significantly increases the economic costs of medical care. The COVID-19 pandemic became a trigger for our scientific considerations. Noticing common elements in the pathogenesis of such various conditions as CC, autoimmune diseases, and COVID-19 makes the question about new applications for old drugs justified. Of note, the effectiveness of most drugs used to date diminishes over time in CC or is restricted due to their side effects. The progression of several cancers may be, however, accelerated by inflammation. A growing body of evidence indicates inflammation as a hallmark of disease that substantially contributes to the progression of malignancies [43] . It is reasonable to claim that cancer progression exacerbates cachexia, but at the same time, cachexia can accelerate cancer progression. In this situation, it seems conceivable that using old drugs -CQ/HCQ -could be associated with prolonged survival and improved quality of life. If efficacy is confirmed, the proposed treatment would also be cost-effective. Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia Evidence that cytokines play a role in rheumatoid arthritis The genetics and molecular pathogenesis of systemic lupus erythematosus (SLE) in populations of different ancestry Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19 Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1 The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system Definition and classification of cancer cachexia: an international consensus Cancer Cachexia: Beyond Weight Loss An update on promising agents for the treatment of cancer cachexia Medroxyprogesterone acetate in the management of cancer cachexia Cancer cachexia and immunomodulation Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases Development by self-digestion: molecular mechanisms and biological functions of autophagy Autophagy as a regulated pathway of cellular degradation Autophagy: renovation of cells and tissues Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion Re-purposing chloroquine for glioblastoma: potential merits and confounding variables Combination of an autophagy inducer and an autophagy Inhibitor: a smarter strategy emerging in cancer therapy Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer Chloroquine and hydroxychloroquine for cancer therapy Chloroquine enhances the radiosensitivity of bladder cancer cells by inhibiting autophagy and activating apoptosis Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis Interleukin-6 as a potential biomarker of COVID-19 progression Inflammatory bowel disease care in the COVID-19 pandemic era: the Humanitas, Milan experience Analysis of Clinical Features of 29 Patients With Increased Incidence of Gastrointestinal Side Effects in Patients Taking Hydroxychloroquine: A Brand-related Issue Ranking Self-reported Gastrointestinal Side Effects of Pharmacotherapy in Sarcoidosis Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind sixweek trial with eighteen-week extension Hydroxychloroquine retinopathyimplications of research advances for rheumatology care The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology Estimation of cachexia among cancer patients based on four definitions Understanding cachexia as a cancer metabolism syndrome Platinum-induced muscle wasting in cancer chemotherapy: Mechanisms and potential targets for therapeutic intervention Cancer-related inflammation and treatment effectiveness This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declare no conflicts of interest.